Introduction:
The gene therapy market in the United States is experiencing rapid growth, with an increasing number of companies importing gene therapy products to meet the rising demand. In 2026, the top 30 premier gene therapy importers in the United States are playing a crucial role in shaping the market landscape. With a focus on innovation and cutting-edge technology, these importers are driving advancements in the field of gene therapy.
Top 30 Premier Gene Therapy Importers in United States 2026:
1. Pfizer
2. Novartis
3. Biogen
4. Amgen
5. Gilead Sciences
6. Regeneron Pharmaceuticals
7. Vertex Pharmaceuticals
8. Bristol-Myers Squibb
9. AbbVie
10. Eli Lilly and Company
11. Johnson & Johnson
12. Merck & Co.
13. Roche
14. Sanofi
15. AstraZeneca
16. Moderna
17. Sarepta Therapeutics
18. Bluebird Bio
19. Spark Therapeutics
20. CRISPR Therapeutics
21. Editas Medicine
22. Intellia Therapeutics
23. Beam Therapeutics
24. Homology Medicines
25. Sangamo Therapeutics
26. Orchard Therapeutics
27. Ultragenyx Pharmaceutical
28. Regenxbio
29. Solid Biosciences
30. AveXis
Insights:
The gene therapy market in the United States is expected to continue its upward trajectory, driven by factors such as increasing investment in research and development, growing prevalence of genetic disorders, and rising demand for personalized medicine. According to industry reports, the gene therapy market is projected to reach $10 billion by 2026, with a compound annual growth rate of 25%. This presents significant opportunities for importers to capitalize on the expanding market and drive innovation in gene therapy products. As the industry continues to evolve, collaboration between importers, manufacturers, and regulatory bodies will be crucial in ensuring the safe and effective delivery of gene therapy products to patients in need.
Related Analysis: View Previous Industry Report
